SCHEMBL20209014

SCHEMBL20209014

Cc1c(O)ccc2c3c(c(=O)oc12)CNCC3

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.69
KDM4E B2RXH2 3/20 0.68
ALDH1A1 P00352 3/20 0.68
GAA P10253 3/20 0.68
GLA P06280 2/20 0.68
HPGD P15428 2/20 0.68
CASP1 P29466 2/20 0.68
CASP7 P55210 2/20 0.68
HSD17B10 Q99714 2/20 0.68
MAOA P21397 2/20 0.68
MAPK1 P28482 1/20 0.68
LMNA P02545 1/20 0.56
ESR2 Q92731 11/20 0.51
ESR1 P03372 7/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
MAOB P27338 1/20 0.47
GBA1 P04062 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL31535365 0.95 ERN1 (0.67) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL17618267 0.82 ERN1 (1.00) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL16198368 0.78 ERN1 (1.00) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL20209031 0.77 ERN1 (0.48) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL20209030 0.77 MTHFD2 (0.51) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL22882603 0.77 ERN1 (0.77) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL31535277 0.76 ERN1 (0.47) ERN1KDM4EALDH1A1GAAGLA
Hydrochloric Acid SCHEMBL21354084 0.76 MTHFD2 (0.50) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL22882605 0.75 ERN1 (0.66) ERN1KDM4EALDH1A1GAAGLA
SCHEMBL20208566 0.74 ERN1 (0.46) ERN1KDM4EALDH1A1GAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
EP-3546463-B1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO CO LTD (JP) 2022-12-07 EP disclosed
US-10774087-B2 Sulfonamide derivative having coumarin skeleton DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-09-15 US disclosed
EP-3546463-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON Daiichi Sankyo Co., Ltd. (JP) 2019-10-02 EP disclosed
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-09-19 US disclosed
WO-2018097162-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON 第一三共株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284198-A1 SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON MTHFD1, MTHFD2, DHFR ERN1 2490/4885KDM4E 3782/4885ALDH1A1 220/4885
US-10774087-B2 Sulfonamide derivative having coumarin skeleton MTHFD1, MTHFD2, DHFR ERN1 2490/4885KDM4E 3782/4885ALDH1A1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.